Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.

TitleSevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.
Publication TypeJournal Article
Year of Publication2014
AuthorsSandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT
Corporate AuthorsAIDS Clinical Trials Group A5296 Team
JournalJ Infect Dis
Volume210
Issue10
Pagination1549-54
Date Published2014 Nov 15
ISSN1537-6613
KeywordsAdult, Antigens, CD14, Bacterial Translocation, Cardiovascular Agents, Cardiovascular Diseases, Cholesterol, LDL, HIV Infections, Humans, Lipopolysaccharides, Lipoproteins, LDL, Male, Middle Aged, Polyamines, Sevelamer, Thromboplastin, Treatment Outcome, Young Adult
Abstract

UNLABELLED: Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits.

CLINICAL TRIALS REGISTRATION: NCT 01543958.

DOI10.1093/infdis/jiu305
Alternate JournalJ. Infect. Dis.
PubMed ID24864123
PubMed Central IDPMC4215074
Grant List2UM1AI069412-08 / AI / NIAID NIH HHS / United States
2UM1AI069432 / AI / NIAID NIH HHS / United States
2UM1AI069452-08 / AI / NIAID NIH HHS / United States
2UMIAI069511-08 / / PHS HHS / United States
5-P30-AI-045008-15 / AI / NIAID NIH HHS / United States
5U01 AI069502-07 / AI / NIAID NIH HHS / United States
A1-069513 / / PHS HHS / United States
AI-076174 / AI / NIAID NIH HHS / United States
AI-68634 / AI / NIAID NIH HHS / United States
AI069471 / AI / NIAID NIH HHS / United States
AI069477 / AI / NIAID NIH HHS / United States
AI069501 / AI / NIAID NIH HHS / United States
P30-AI027757 / AI / NIAID NIH HHS / United States
R00 HL108743 / HL / NHLBI NIH HHS / United States
U01 AI-68636 / AI / NIAID NIH HHS / United States
U01 AI069412 / AI / NIAID NIH HHS / United States
UL1 RR024160 / RR / NCRR NIH HHS / United States
UL1 TR001082 / TR / NCATS NIH HHS / United States
UL1 TR001082 / TR / NCATS NIH HHS / United States
UL1TR000124 / TR / NCATS NIH HHS / United States
UM1 AI068634 / AI / NIAID NIH HHS / United States
UM1 AI068636 / AI / NIAID NIH HHS / United States
UM1 AI069412 / AI / NIAID NIH HHS / United States
UM1 AI069424 / AI / NIAID NIH HHS / United States
UM1 AI069477 / AI / NIAID NIH HHS / United States
UM1 AI069496 / AI / NIAID NIH HHS / United States
UM1 AI069534 / AI / NIAID NIH HHS / United States
UM1 AI106701 / AI / NIAID NIH HHS / United States
UM1-A1069424 / / PHS HHS / United States
UM1-AI068636 / AI / NIAID NIH HHS / United States
UM1-AI069534-08 / AI / NIAID NIH HHS / United States
UM1AI069495 / AI / NIAID NIH HHS / United States